OGX-427

Type: Product

Name: OGX-427

First reported May 13 2013 - Updated May 13 2013 - 1 reports

OncoGenex Pharmaceuticals initiates Phase II bladder cancer trial

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, has initiated the Borealis-2 clinical trial, an investigator-sponsored, randomized Phase II trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder ... [Published Individual.com - May 13 2013]

Entities: Bladder Cancer, OGX-427, OncoGenex Pharmaceuticals, docetaxel

First reported May 10 2013 - Updated May 10 2013 - 1 reports

OncoGenex to initiate Phase II metastatic pancreatic cancer trial

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, has announced plans to initiate the Rainier trial, an investigator-sponsored, randomized, placebo-controlled Phase II trial evaluating OGX-427 in combination with ABRAXANE and gemcitabine in ... [Published Individual.com - May 10 2013]

Entities: Pancreatic Cancer, Metastatic, OncoGenex Pharmaceuticals

First reported May 10 2013 - Updated May 10 2013 - 1 reports

OncoGenex Announces that the Borealis-2 Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced initiation of the Borealis-2? clinical trial, an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 ... [Published NewsRX - May 10 2013]

Entities: OGX-427, OncoGenex Pharmaceuticals, Bladder Cancer, Metastatic

First reported May 06 2013 - Updated May 06 2013 - 1 reports

OncoGenex Loss Lower than Expected - Analyst Blog

OncoGenex Pharmaceuticals, Inc. ( OGXI ) reported first quarter 2013 net loss per share of 46 cents, narrower than the Zacks Consensus Estimate of a loss of 68 cents and the year-ago loss of 67 cents per share.First quarter 2013 revenues were $5.1 million, ... [Published Nasdaq - May 06 2013]

Entities: OncoGenex Pharmaceuticals, OGX-427, Metastatic, non-small cell lung cancer

First reported May 02 2013 - Updated May 03 2013 - 2 reports

OncoGenex Pharmaceuticals Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013

/PRNewswire via COMTEX/ -- OncoGenex Pharmaceuticals, Inc. /quotes/zigman/111981/quotes/nls/ogxi OGXI +1.38% today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter ... [Published BioSpace - May 03 2013]

Entities: OncoGenex Pharmaceuticals, OGX-427, Comtex

First reported May 02 2013 - Updated May 03 2013 - 7 reports

Phase II

OncoGenex Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript

OncoGenex Pharmaceuticals, Inc. (OGXI) Q1 2013 Earnings Call May 2, 2013 4:30 PM ETOperatorGood afternoon, ladies and gentlemen, and welcome to the OncoGenex Update on Clinical Development Programs and Discussion of First Quarter 2013 Financial Results ... [Published Seeking Alpha - May 03 2013]

Entities: OGX-427, OncoGenex Pharmaceuticals, Phase II, Killer Whale, Scott Cormack

First reported May 03 2013 - Updated May 03 2013 - 1 reports

AVEO Pharmaceuticals Inc

AVEO Spurned, ARNA Bleeds, It's Thumbs Up For AGN, OGXI Lists Busy Slate

Allergan Inc.'s (AGN: Quote) experimental device JUVÉDERM VOLUMA XC, an injectable hyaluronic acid dermal filler for cheek augmentation to correct age-related volume deficit in the mid-face, on Thursday won the unanimous backing of an FDA advisory pa ... [Published RTTNews.com - May 03 2013]

Entities: AVEO Pharmaceuticals Inc, OGX-427, Metastatic, Phase III

First reported May 02 2013 - Updated May 02 2013 - 1 reports

AGEN's Brain Cancer Vaccine Works, AVEO On Watch, PSDV Gets Decision Date

Agenus Inc. (AGEN: Quote) said that its brain cancer vaccine candidate - Prophage G-100, plus the standard of care demonstrated a 146% increase in progression free survival and a 60% increase in overall survival compared to the standard of care alone ... [Published RTTNews.com - May 02 2013]

Entities: AVEO Pharmaceuticals Inc, cancer vaccine, Harvard Bioscience Inc, Brain Cancer, Probuphine

First reported Apr 30 2013 - Updated May 01 2013 - 7 reports

OncoGenex (OGXI) to Initiate OGX-427 Phase 2 in Combo with ABRAXANE

OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced plans for the initiation of the Rainier trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with ABRAXANE (paclitaxel protein-bound particles ... [Published Street Insider - May 01 2013]

Entities: OGX-427, Abraxane, OncoGenex Pharmaceuticals

First reported Apr 12 2013 - Updated Apr 13 2013 - 2 reports

OncoGenex to initiate phase II trial of OGX-427 in non-squamous NSCLC

OncoGenex Pharmaceuticals, a biopharmaceutical company, plans to initiate an investigator-sponsored, randomized, double-blind, placebo-controlled phase II study, Spruce, evaluating OGX-427 in patients with previously untreated advanced non-squamous non-small ... [Published Center Watch - Apr 13 2013]

Entities: OGX-427, non-small cell lung cancer, OncoGenex Pharmaceuticals, Pemetrexed

First reported Mar 26 2013 - Updated Mar 26 2013 - 1 reports

OncoGenex's Second Cancer Drug Gaining Investor Attention

By Len Zehr : Even though OncoGenex Pharmaceuticals ( OGXI ) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company's second generation antisense drug, OGX-427. "We ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 26 2013]

Entities: OncoGenex Pharmaceuticals, OGX-427, Scott Cormack, malignancy, Drugs

First reported Feb 13 2013 - Updated Feb 14 2013 - 2 reports

OncoGenex to begin Borealis-2 trial evaluating OGX-427 in combo with second-line therapy for bladder cancer

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company committed to the development and commercialization of new therapies, has planned to initiate Borealis-2 clinical trial, an investigator-sponsored, randomized, controlled phase II study evaluating ... [Published PharmaBiz - Feb 14 2013]

Entities: OGX-427, Bladder Cancer, OncoGenex Pharmaceuticals, docetaxel

Quotes

...stated Noah M Hahn MD, Associate Professor of Medicine at Indiana University Simon Cancer Center and one of the primary investigators on the trial. "We hope that this trial will shed new light on the role of Hsp27 in bladder cancer and the ability of OGX-427 to work synergistically with second- or third-line chemotherapy to overcome resistance and prolong survival."

OncoGenex Pharmaceuticals initiates Phase II bladder cancer trial [Published Individual.com - May 13 2013]

...Professor of Medicine, Division of Hematology/Oncology at the University of California San Francisco, and a primary investigator on the trial. "The Rainier trial provides us the opportunity to explore the role of Hsp27 in pancreatic cancer, and the potential ability of OGX-427 to improve on clinical outcomes when added to combination chemotherapy."

OncoGenex to initiate Phase II metastatic pancreatic cancer trial [Published Individual.com - May 10 2013]

...clinical benefits to patients with unresectable metastatic ocular melanoma in the liver" said Eamonn P Hobbs, President and CEO of Delcath Systems. "While we were disappointed in today's outcome, we will continue to work closely with the FDA throughout its ongoing evaluation of Melblez Kit. We remain committed to providing access to this promising new treatment for patients who have few choices with regard to treatments."

Delcath Confirms FDA Panel Voted 16-0 Against Melblez Kit; AVEO, Astellas Confirm Unfavorable Vot ... [Published BioMedReports - May 03 2013]

"The initiation of multiple investigator-sponsored Phase 2 trials, across tumor types, represents a significant inflection point in the creation of value for OGX-427 for which we currently retain all commercialization rights" said Scott Cormack

OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financ ... [Published WTNZ - May 02 2013]

More Content

sort by: Date \| Relevance
OncoGenex Pharmaceuticals initiates Phase II bl... [Published Individual.com - May 13 2013]
OncoGenex to initiate Phase II metastatic pancr... [Published Individual.com - May 10 2013]
OncoGenex Announces that the Borealis-2 Clinica... [Published NewsRX - May 10 2013]
OncoGenex Loss Lower than Expected - Analyst Blog [Published Nasdaq - May 06 2013]
OncoGenex Pharmaceuticals Inc. Provides Clinica... [Published BioSpace - May 03 2013]
OncoGenex Pharmaceuticals' CEO Discusses Q1 201... [Published Seeking Alpha - May 03 2013]
OncoGenex to begin Rainier clinical trial evalu... [Published PharmaBiz - May 03 2013]
AVEO Spurned, ARNA Bleeds, It's Thumbs Up For A... [Published RTTNews.com - May 03 2013]
Delcath Confirms FDA Panel Voted 16-0 Against M... [Published Equities.com - May 03 2013]
Delcath Confirms FDA Panel Voted 16-0 Against M... [Published BioMedReports - May 03 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published WTNZ - May 02 2013]
OncoGenex Pharmaceuticals Provides Clinical Dev... [Published Equities.com - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published Bio-Medicine - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published Yahoo! Finance - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published StockHouse USA - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published Canada NewsWire - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published PR Newswire: Health - May 02 2013]
AGEN's Brain Cancer Vaccine Works, AVEO On Watc... [Published RTTNews.com - May 02 2013]
OncoGenex (OGXI) to Initiate OGX-427 Phase 2 in... [Published Street Insider - May 01 2013]
OncoGenex Announces Plans for the Initiation of... [Published Equities.com - May 01 2013]
HIL, OGXI, ANTH, NPTN Expected To Be Down After... [Published Individual.com - May 01 2013]
OncoGenex to Initiate Rainier Clinical Trial Ev... [Published Benzinga.com - May 01 2013]
OncoGenex Announces Plans for the Initiation of... [Published Yahoo! Finance - May 01 2013]
OncoGenex Announces Plans for the Initiation of... [Published PR Newswire: Health - May 01 2013]
Delcath Says FDA Posted Briefing Documents Ahea... [Published BioMedReports - May 01 2013]
OncoGenex Announces that the Borealis-2T Clinic... [Published Equities.com - Apr 30 2013]
OncoGenex Announces that the Borealis-2™ Clinic... [Published ADVFN India - Apr 30 2013]
OncoGenex Announces that the Borealis-2™ Clinic... [Published Canada NewsWire - Apr 30 2013]
OncoGenex Announces that the Borealis-2™ Clinic... [Published PR Newswire: Health - Apr 30 2013]
Metastatic Hormone Refractory (Castration Resis... [Published Individual.com - Apr 23 2013]

Blogs

sort by: Date \| Relevance
OncoGenex to begin Spruce clinical trial to eva... [Published PBR - News - Apr 12 2013] OncoGenex is planning to begin the Spruce clinical trial to assess OGX-427 in combination with chemotherapy in treatment of naive patients with advanced non-squamous non-small cell lung cancer (NSCLC). ...
4 Healthcare Stock Stories for Mid-Week Wellness [Published Wall St. Cheat Sheet - Feb 13 2013] Amarin Corporation ( NASDAQ:AMRN ): Current price $8.56 Amarin reported Tuesday that the United States Patent and Trademark Office has published notification for Patent Application Serial Number 13/614,129, which includes claims intended to protect ...
InPlay from Briefing.com [Published MaritimeSecurity.Asia - Feb 13 2013] 7:02 pm Limoneira announces the annexation of East Area 1 into the city of Santa Paula ( LMNR ) : Co announced that on February 12, 2013, East Area 1 was formally annexed into Santa Paula. The annexation was the final required step to enable Limoneira ...

Press Releases

sort by: Date \| Relevance
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published PR Newswire: Health - May 02 2013]
OncoGenex Announces Plans for the Initiation of... [Published PR Newswire: Health - May 01 2013]
OncoGenex Announces that the Borealis-2™ Clinic... [Published PR Newswire: Health - Apr 30 2013]
Research and Markets: Non Muscle Invasive Bladd... [Published Business Wire - Apr 22 2013]
OncoGenex Announces Plans for the Initiation of... [Published PR Newswire: Health - Apr 11 2013]